AcroMeta Group Limited (SGX: 43F) announced today that it has entered into a non-binding term sheet with Macro HRD SG Pte. Ltd. to form a strategic partnership aimed at entering the ambient temperature cellular logistics (ATCLS) industry. The proposed partnership would see AcroMeta acquire a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercialising Macro's ATCLS technology, and secure an option to obtain an exclusive licence to deploy the technology across Southeast Asia.
The ATCLS technology, developed by Macro HRD, is designed to transport living cells and other temperature-sensitive biological materials at ambient temperatures, eliminating the need for conventional refrigerated or cryogenic cold chains. This is achieved through proprietary preservation and reactivation methods, supported by the Gradient Equilibrium Decision Modeling (GEDM) platform, which provides real-time governance, chain-of-identity, and process control. The technology enables dormant cells to be transported at ambient temperature and reactivated at the point of use, potentially reducing costs and expanding geographic reach for cell-based therapies.
The market potential for this technology is significant, with the global cell-and-gene-therapy 3PL market estimated at US$1.81 billion in 2025 and projected to grow at a 25.1% CAGR to reach US$16.95 billion by 2035. Underlying markets such as immune-cell therapy and organ transplantation are valued at US$5.2 billion and US$47 billion, respectively. Macro's management estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032 for the ambient-addressable segments. AcroMeta's executive director, Lawrence Toh, noted, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead."
Under the term sheet, AcroMeta will have the option to acquire an exclusive licence to deploy ATCLS technology in agreed Southeast Asian territories, including the right to appoint sub-licensees. This structure also provides a first right to acquire additional territories, expanding the Group's potential commercial reach. The partnership aligns with AcroMeta's strategy to diversify its portfolio beyond its core facility management operations and pursue long-term growth opportunities.
The agreement is non-binding, and the final terms are subject to due diligence and negotiation of definitive agreements. The Group intends to continue evaluating strategic opportunities to support shareholder value creation. The information regarding market sizes and projections was provided by Macro's management and has not been independently verified by AcroMeta's board of directors.
